Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies1

Autor: Veskimäe, K, Scaravilli, M, Niininen, W, Karvonen, H, Jaatinen, S, Nykter, M, Visakorpi, T, Mäenpää, J, Ungureanu, D, Staff, S

Publikováno v: Translational Oncology

Ovarian cancer has the highest mortality rate of all gynecologic malignancies. Identification of new biomarkers is highly needed due to its late diagnosis and high recurrence rate. The objective of this study was to identify mechanisms of therapy res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::129cc143245b6698368afb6f2887c2b4
http://europepmc.org/articles/PMC6079561

New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome.

Autor: Raivola J; Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland., Dini A; Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland., Salokas K; Institute of Biotechnology, HiLife, University of Helsinki, 00014, Helsinki, Finland., Karvonen H; Faculty of Medicine and Health Technology, Tampere University, 33014, Tampere, Finland.; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, USA., Niininen W; Faculty of Medicine and Health Technology, Tampere University, 33014, Tampere, Finland., Piki E; Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland., Varjosalo M; Institute of Biotechnology, HiLife, University of Helsinki, 00014, Helsinki, Finland., Ungureanu D; Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, 00014, Helsinki, Finland. daniela.ungureanu@helsinki.fi.; Faculty of Medicine and Health Technology, Tampere University, 33014, Tampere, Finland. daniela.ungureanu@helsinki.fi.; Faculty of Biochemistry and Molecular Medicine, University of Oulu, 90014, Oulu, Finland. daniela.ungureanu@helsinki.fi.

Publikováno v: Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2022 May 04; Vol. 79 (5), pp. 276. Date of Electronic Publication: 2022 May 04.

Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases.

Autor: Sheetz JB; Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, Yale University West Campus, West Haven, CT 06516, USA., Mathea S; Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Frankfurt am Main 60438, Germany; Buchmann Institute for Molecular Life Sciences, Structural Genomics Consortium, Frankfurt am Main 60438, Germany; German Cancer Consortium DKTK Frankfurt/Mainz, Frankfurt 60438, Germany., Karvonen H; Cancer Signaling, Faculty of Medicine and Health Technology and BioMediTech, Tampere University, Tampere 33014, Finland., Malhotra K; Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, Yale University West Campus, West Haven, CT 06516, USA., Chatterjee D; Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Frankfurt am Main 60438, Germany; Buchmann Institute for Molecular Life Sciences, Structural Genomics Consortium, Frankfurt am Main 60438, Germany., Niininen W; Cancer Signaling, Faculty of Medicine and Health Technology and BioMediTech, Tampere University, Tampere 33014, Finland., Perttilä R; Cancer Signaling, Faculty of Medicine and Health Technology and BioMediTech, Tampere University, Tampere 33014, Finland., Preuss F; Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Frankfurt am Main 60438, Germany; Buchmann Institute for Molecular Life Sciences, Structural Genomics Consortium, Frankfurt am Main 60438, Germany., Suresh K; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA., Stayrook SE; Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, Yale University West Campus, West Haven, CT 06516, USA., Tsutsui Y; Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, Yale University West Campus, West Haven, CT 06516, USA., Radhakrishnan R; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA., Ungureanu D; Cancer Signaling, Faculty of Medicine and Health Technology and BioMediTech, Tampere University, Tampere 33014, Finland; Genome-Scale Biology, Research Programs Unit, University of Helsinki, Helsinki 00014, Finland. Electronic address: daniela.ungureanu@tuni.fi., Knapp S; Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Frankfurt am Main 60438, Germany; Buchmann Institute for Molecular Life Sciences, Structural Genomics Consortium, Frankfurt am Main 60438, Germany; German Cancer Consortium DKTK Frankfurt/Mainz, Frankfurt 60438, Germany. Electronic address: knapp@pharmchem.uni-frankfurt.de., Lemmon MA; Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Yale Cancer Biology Institute, Yale University West Campus, West Haven, CT 06516, USA. Electronic address: mark.lemmon@yale.edu.

Publikováno v: Molecular cell [Mol Cell] 2020 Aug 06; Vol. 79 (3), pp. 390-405.e7. Date of Electronic Publication: 2020 Jul 02.

Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways.

Autor: Karvonen H; Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.; Tays Cancer Center, Tampere University Hospital, 33520 Tampere, Finland., Barker H; Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland., Kaleva L; Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.; Tays Cancer Center, Tampere University Hospital, 33520 Tampere, Finland., Niininen W; Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.; Tays Cancer Center, Tampere University Hospital, 33520 Tampere, Finland., Ungureanu D; Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland. daniela.ungureanu@tuni.fi.; Tays Cancer Center, Tampere University Hospital, 33520 Tampere, Finland. daniela.ungureanu@tuni.fi.

Publikováno v: Cells [Cells] 2019 Aug 02; Vol. 8 (8). Date of Electronic Publication: 2019 Aug 02.

Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies.

Autor: Li L; State Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China., Huang W; State Key Laboratory of Chemical Biology, Research Center of Chemical Kinomics, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, China., Ren X; State Key Laboratory of Chemical Biology, Research Center of Chemical Kinomics, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, China., Wang Z; State Key Laboratory of Chemical Biology, Research Center of Chemical Kinomics, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, China., Ding K; State Key Laboratory of Chemical Biology, Research Center of Chemical Kinomics, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, China. dingk@sioc.ac.cn., Zhao L; State Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China. zhaolinxiang@syphu.edu.cn., Zhang J; State Key Laboratory of Chemical Biology, Research Center of Chemical Kinomics, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, China. jinweizhang@sioc.ac.cn.

Publikováno v: Science China. Life sciences [Sci China Life Sci] 2024 Aug 12. Date of Electronic Publication: 2024 Aug 12.